Novartis wants Japan to link drug price to patient outcomes

to The Nikkei in a recent interview. Japan has never implemented such a payment scheme. At issue is Kymriah, a new treatment for acute lymphoblastic leukemia in children and young adults. Kymriah in August became the first CAR-T cell therapy — one that …
( read original story …)


Related Post

Tokyo all smiles as it takes stock of Trump’s nasc...
views 185
News reports say a summit with Abe is likely to be...
Hyderabad falters on collecting domestic waste
views 213
HYDERABAD: While the Telangana government is busy ...
Ex-Tiger McGehee signs 1-year deal with Japan'...
views 170
We want you to tell us what you think of our artic...
Japan’s economy likely stalled in first-quar...
views 42
Despite a solid economy, consumer prices have been...
Olympic Gold Medalist Jeremy Wariner Retires After...
views 144
Ten years after running 43.45 for 400 meters at th...
Nikkei slips from 2-yr highs as tech shares fall; ...
views 121
TOKYO, Sept 26 (Reuters) - Japan’s Nikkei average ...
Japan's Constitution turns 70; PM Abe calls f...
views 174
"Now is the time to look to the future, in anticip...
Japanese-style cheesecake
views 53
Note: The use of parchment paper here is a must. M...
Tokyo assures Dar of continued financial support
views 159
THE embassy of Japan has assured Tanzania of its c...
Japanese stocks to rise in 2017
views 195
TOKYO: Japan’s Nikkei is set to end slightly...